Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
subclass B2 metallo-beta-lactamase PFM-1
Overview
| Allele | Database | Papers | Drug Classes | Organisms | Countries | Years | Sequence Accession | Protein Accession |
|---|---|---|---|---|---|---|---|---|
| blaPFM-1 | Card DatabaseReference Gene CatalogReslit | 5 | CARBAPENEM, ceftazidime +2 | Pseudomonas fluorescens +2 | Asia/South Pacific|Europe|Latin America|Middle East/Africa|North America | 2024 | MN065826.1 | QDC33502.1 |
| blaPFM-2 | Card DatabaseReference Gene Catalog | 3 | CARBAPENEM | Pseudomonas libanensis | - | - | MN080496.1 | QGJ02506.1 |
| blaPFM-3 | Card DatabaseReference Gene Catalog | 3 | CARBAPENEM | Pseudomonas fluorescens | - | - | MN080497.1 | QGJ02507.1 |
| blaPFM-5 | Reference Gene Catalog | 1 | CARBAPENEM | Pseudomonas fluorescens | - | - | PV244044.1 | XPT09377.1 |
| blaPFM-4 | Card DatabaseReference Gene Catalog | 2 | CARBAPENEM | Pseudomonas sp. BF61 | - | 2022 | JACOMR010000005.1 | MBU4627809.1 |
BioF is a novel B2 metallo-β-lactamase from Pseudomonas sp. isolated from an on-farm biopurification system.
BioF is a novel B2 metallo-β-lactamase from Pseudomonas sp. isolated from an on-farm biopurification system.
Relative inhibitory activities of the broad-spectrum beta-lactamase inhibitor taniborbactam against metallo-beta-lactamases.
The study evaluates the inhibitory activity of taniborbactam against various metallo-beta-lactamases (MBLs), demonstrating that it effectively inhibits most NDM- and VIM-like enzymes but not SIM-1. Specific mutations in VIM-1 and NDM-1 were found to confer resistance to taniborbactam.
Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.
Cefepime-taniborbactam showed potent in vitro activity against Enterobacterales and P. aeruginosa, particularly effective against isolates with carbapenemase genes such as blaIMP, blaNDM, and blaVIM, as well as those with mutations in ftsI, ompK35, and ompK36.
No comments yet. Be the first to comment!